The Acute Gout Flare Treatment Market is anticipated to experience a swift surge in revenue with a compounded annual growth rate (CAGR) during the projected period from 2019 to 2030. This escalation is attributed to the escalating number of ongoing clinical trials aimed at introducing novel and safe treatment alternatives.
Gout, a type of inflammatory arthritis, manifests when the levels of uric acid in the body reach a critical threshold. During a gout flare, a joint can become suddenly excruciatingly painful, tender, inflamed, and swollen, with this discomfort persisting for several days or even weeks.
Furthermore, the initial site of redness and swelling in cases of acute gout flares is often the big toe. However, gout flare-ups can also affect other areas of the body, including the wrists, fingers, elbows, feet, ankles, and knees.
Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/5671
Market Growth Catalysts: Drivers: The expansion of market revenue is steered by factors such as the escalating research pipeline focused on developing innovative anti-gout medications. For instance, Arthrosi Therapeutics is set to initiate a phase 2 clinical trial in December 2019 to assess the safety and tolerance of AR882, a candidate medication, when administered alone or in combination with febuxostat or allopurinol in gout patients. Completion of this investigation is projected by June 2020.
Moreover, the market for gout treatment is projected to thrive due to the increased approvals of products by regulatory agencies. Additionally, the introduction of generic versions of anti-gout drugs is expected to offer growth prospects for market participants, allowing them to expand their presence in the gout disease treatment market.
Restraints: Opportunities: The escalating prevalence of cancer has heightened the demand for effective treatments. Leading global firms are allocating significant portions of their revenues towards research and development (RD) efforts to innovate advanced drugs. Numerous products centered around sophisticated pharmaceutical delivery systems are pending clearance from the U.S. Food and Drug Administration (FDA). The overall advancement of the market is projected to be propelled by the surging need for cutting-edge medications to address conditions like malignant mesothelioma.
Furthermore, the concept of personalized medicine, which has been subtly acknowledged in the medical field since the 1960s, holds substantial promise. This concept gained more attention with its first mention in a monograph title in 1998 and subsequent publication on the Medline interface in 1999. Advancements in genetic technologies, particularly Single Nucleotide Polymorphism (SNP) genotyping and microarray/biochips, have been instrumental in driving personalized medicine. Any strides made in this realm would present significant opportunities for key market players to thrive.
Geographic Market Landscape: Region with Highest Revenue Share: The North American region is poised to capture the largest market share throughout the forecast period. This dominance is attributed to the presence of major local players, widespread utilization of gout treatments, the high cost of name-brand medications in the U.S., and the introduction of urate-lowering medicines.
To know more about the latest insights of the report, visit @
https://www.reportsanddata.com/request-latest-insight/5671
Region with the Fastest Revenue Growth Rate: The Asia Pacific region is projected to achieve the highest CAGR during the forecast period due to its high prevalence rate of gout, increasing healthcare expenditures, and adoption of newer technologies and therapeutic advancements that will drive revenue growth.
Key Market Trends and Innovations: Novartis Pharmaceuticals is currently conducting a phase 3 clinical trial to assess the safety and efficacy of Canakinumab 150mg in patients suffering from acute gouty arthritis. A phase 2 clinical trial is underway to evaluate the drug Anakinra 100mg in patients experiencing acute gout flare with Chronic Kidney Disease. GeneScience Pharmaceuticals Co., Ltd. is conducting a phase 1 clinical trial on the drug Genakumab for the treatment of patients with acute gout flare.
Organic and Inorganic Strategies: In December 2021, the FDA approved the use of Lesinurad (Zurampic) in combination with allopurinol or febuxostat for the treatment of hyperuricemia associated with gout flare. In December 2018, SunGen Pharma received FDA approval for Prednisone (Deltasone), a drug available in various strengths (10 mg, 20 mg, and 50 mg tablets) for the treatment of conditions such as arthritis, gout, blood disorders, immune system disorders, and others.
Prominent Companies in the Market: Key players include:
- Savient Pharmaceuticals
- Takeda Pharmaceutical Company Ltd.
- Novartis AG
- AstraZeneca plc.
- Merck Co., Inc.
- Teijin Pharma Ltd.
- Regeneron Pharmaceuticals
Significance of Our Report and Advantages: Our report furnishes historical data, forecasts, and revenue growth analyses on a global, regional, and country level. It provides insights into industry trends, consumption patterns, and detailed analyses for each region, major country, and segment from 2019 to 2030. The global market report covers industry trends, drivers, restraints, opportunities, threats, market strategies, segment revenue, and the contribution of each regional and country market. Moreover, the report includes industry analysis, competitive landscape, company financials, and impact analysis.
Outlook on Drug Classes (Revenue, USD Billion; 2019-2030):
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Corticosteroids
- Colchicine
- Urate-Lowering Agents
- Others
By Type of Product Outlook (Revenue, USD Billion; 2019-2030):
- Tablets
- Capsules
- Parenterals
- Others
By Distribution Channel Outlook (Revenue, USD Billion; 2019-2030):
- Online Distribution
- Offline Distribution
By Route of Administration Outlook (Revenue, USD Billion; 2019-2030):
- Oral
- Parenteral
- Others
By End-User Outlook (Revenue, USD Billion; 2019-2030):
- Hospitals
- Specialty Clinics
- Others
Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/5671
Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.
Browse for more reports:
Advanced Ophthalmology Technologies Market
Electrocardiogram (ECG) Management Systems Market
Nonmydriatic Handheld Fund Camera Market
Empty Intravenous (IV) Bags Market
Hangover Rehydration Supplements Market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
